Kena betancur | Corbis News | Getty pictures
Pfizer On Monday, a patient said that the experimental daily weight loss pill will end after experiencing a potential liver injury by a convicted medication.
The patient did not experience symptoms or side effects associated with the liver, a Pfizer spokesman said in a statement. They added that the patient’s liver enzymes “quickly recovered”, after taking a pill-1 drug from the mouth called Danuglipron, “he recovered rapidly.” Statement shows that the patient’s liver enzymes often rise damage to cells It is an issue related to the body and some other obesity drugs.
During the period of preparation, the court took place in the trial quickly increasing the dose of the pill. Pfizer’s decision to stop the development of the drug “To date, so far to date to date, including the recommendation of information, including the recent entrances of the information,” the sum of information, including the sum of information, “.
“When we stop developing Danugliprron, we remain committed to evaluating and developing promising programs to bring new medicines to the patients,” said Dr. Chris Boshoff, Pfizer’s senior scientist and released. He added that the company still develops other weight loss medications.
The announcement is a number of a number of a number of a number of a number of a number with a series of a number with a company’s offer to gain a slice market for GLP-1s, which imitates certain intestinal hormones to lower the appetite and adjust the blood sugar. Pfizer is one of the few druggists in a row to bring a pound of pounds a more convenient weight to a place of weekly injections, but for years behind rivals such as Eli lilli and Novo Nordisk.
Some Wall Street analysts expect the GLP-1 industry to be more than $ 150 billion in the early 2030s. According to some analytical calculations, the rest of the injections may be worth $ 50 billion.
This is Danugliprron, Pfizer, is not particularly retreat. The company suspended twice a version of the pill in December 2023.
However, Pfizer said that in the second half of the year, to evaluate more than one dose of pills, he said he would start conducting research in the second half of the year
Despite the decision to break the drug, Pfizer said that these studies meet with the main goals and the potential of the pill and the potential to convey the “competition efficiency and endurance”.
The company also noted that speed is High liver enzymes In people who receive Danugliprron, more than 1,400 patients receiving Pfizer’s pill correspond to approved GLP-1 medications based on the security database.
Pfizer, daily obesity pill in June 2023, after patients receiving this medicine, the average phased patients reached the higher liver enzment. Investors have been a pessimistic about the company’s potential since today.
Still there is pfizer Other experimental In the early stages of development, obesity drugs in the pipeline are now working differently. This includes a medicinal medication that blocks another intestinal hormone, once a daily oral GLP-1 once a day once a time last year.
Pfizer believes that a drug targeting can be more effective and more effective for patients to endure patients, since the company since today, the company has reported to investors in October since the company. Added that “there is so much application for GLP-1S.”
Pfizer’s Danugliprron promotes weight loss by targeting GLP-1, which is also a novo nordiskin weight loss injection wegovy and diabetes treatment ozempical work. Eli Lilly’s weight loss Injection Zepbound and Diabetes Shot Mounjaro Target GLP-1, also activate another intestinal hormone called GIP.
So far, the only oral GLP-1 approved by the Department of Food and Drug Administration is Rybelsus, who is treated by $ 2.38 billion in diabetes Sales In 2024.
The announcement of the Pfizer is Monday, the company restores his feet and restores the price of sharing after the fast descent of the cavid work. Pfizer bets on the pipeline of cancer drugs to ensure long-term growth, but stressed that the main focus of fat.
